Idrossiclorochina Doc

Hydroxychloroquine, the active ingredient in Idrossiclorochina Doc, is an antimalarial presented as an oral tablet for oral use. It is employed to treat malaria and to manage autoimmune disorders such as rheumatoid arthritis and systemic lupus erythematosus in adult patients.

GNH USA supplies Idrossiclorochina Doc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Hydroxychloroquine is an antimalarial and immunomodulatory agent used in several autoimmune conditions.

- Malaria: treats acute uncomplicated malaria caused by susceptible Plasmodium species. - Rheumatoid arthritis: reduces joint inflammation and disease activity. - Systemic lupus erythematosus: helps control disease flares and cutaneous manifestations.

Hydroxychloroquine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools, often transient. - Skin rash: erythematous or pruritic lesions. - Headache: mild to moderate intensity. - Visual disturbances: blurred vision or difficulty focusing. - Loss of appetite: reduced food intake.

Serious or Rare Side Effects: - Retinopathy: progressive vision loss requiring ophthalmologic monitoring. - Cardiac toxicity: QT interval prolongation and arrhythmias. - Severe hypersensitivity: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, consider patient‑specific factors and monitor appropriately.

- Baseline eye exam: assess retinal health prior to treatment. - Cardiac assessment: evaluate QT interval in patients with cardiac risk. - Renal function: adjust use in severe renal impairment. - Pregnancy: weigh potential risks and benefits; consult obstetric guidance. - Concomitant drugs: review for interactions that may increase toxicity. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Hydroxychloroquine can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - QT‑prolonging agents (e.g., quinidine, amiodarone): increased risk of arrhythmia. - Antacids containing aluminum or magnesium: reduce absorption of hydroxychloroquine. - Cytochrome P450 inhibitors (e.g., ketoconazole): may raise plasma concentrations.

Moderate Interactions (Monitor Closely): - CYP2D6 substrates (e.g., metoprolol): possible altered metabolism. - Insulin or oral hypoglycemics: enhanced hypoglycemic effect. - Digoxin: potential increase in serum levels.